期刊文献+

冠脉内注射替罗非班治疗急诊介入术中冠脉无复流的疗效分析 被引量:1

下载PDF
导出
摘要 为总结急性心肌梗死(AMI)急诊经皮冠状动脉介入术(PCI)中发生冠脉无复流时,冠脉内注射替罗非班治疗的疗效,将AMI急诊PCI术中发生冠脉无复流89例患者随机分为替罗非班治疗组(n=45)和对照组(n=44),20min后行冠脉造影观察冠脉血流情况,术后90min比较术前以及两组间心电图变化,术后1周内两组主要终点事件发生率:出血并发症发生情况。结果表明,替罗非班组用药20min后88.9%的患者冠脉血流恢复TIMl2~3级,高于对照组的43.2%,术后90min心电图明显改善,缺血导联数减少,1周内主要终点事件中死亡、顽固性缺血、再次心肌梗死发生率明显低于对照组(P〈0.05),严重出血并发症发生率两组无明显差异。结论:AMI急诊PCI发生冠脉无复流时,冠脉内注射替罗非班可以明显改善术中冠脉血流,减少术后1周内主要终点事件发生,不会增加严重出血并发症。
出处 《沈阳部队医药》 2007年第6期367-369,共3页
  • 相关文献

参考文献2

二级参考文献25

  • 1[1]Peerlinck K,De Lepeleire I,Goldberg M,et al.MK-383(L-700,46 2),a selective nonpeptide platelet glycoprotein Ⅱb/Ⅲa antagonist,is active in man[J].Circulation,1993,88(4,Part1)∶1512-1517.
  • 2[2]Joseph J,Lynch JR,Jacquelynn JC,et al.Nonpeptide glycoprotein Ⅱb/Ⅲa inhibitors.5.antithrombotic effects of MK-0383[J].J Pharmacol Exp Ther ,1995,272(1)∶20-32.
  • 3[3]FDA.MERCK&CO.,INC.West Point,PA 19486,USA [EB/OL].http://www.fda.gov/cd er/foi/label/1998/20913lbl.pdf.2000-08-15.
  • 4[4]FDA.NDA#20-912 Aggrastat Medical/Stastical Review [EB/OL].http://www.f da.gov/cardiovascular and renal drugs advisory committee.html.1998-02-15.
  • 5[5]Alexander JH,Harrington RA.Recent antiplatelet drug trails in the acute c ornary syndromes[J].Drugs,1998,56(6)∶965-976.
  • 6[6]McClellan KJ,Goa KL.Tirofiban[J].Drugs,1998,56(6)∶1067- 1080.
  • 7[1]Elmouchi DA,Bates ER.Platelet glycoprotein Ⅱb/Ⅲa inhibitor therapy in non-ST segment elevation acute coronary syndromes[J].Minerva Cardioangiol,2003,51 (5):547-560.
  • 8[2]Valgimigli M,Percoco G,Malagutti P,et al.Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial[J].JAMA,2005,293 (17):2109-2117.
  • 9[3]Heitzer,T Ollmann,I Koke,K et al.Platelet Glycoprotein Ⅱb/Ⅲa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease[J].Circulation,2003,108 (5):536-541.
  • 10[4]Warnholtz A,Ostad MA,Heitzer T,et al.Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J].Am J Cardiol,2005,95 (1):20-23

共引文献142

同被引文献27

  • 1杨新春,张大鹏,王乐丰,徐立,葛永贵,王红石,李惟铭,倪祝华,夏昆,连勇,薛永利,马利祥.冠状动脉内应用国产替罗非班对急性ST段抬高心肌梗死急诊介入治疗后心肌灌注和临床预后的影响[J].中华心血管病杂志,2007,35(6):517-522. 被引量:73
  • 2Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprmein II h/IIIma inhibitors in acute coronary syndromes: a recta-analysis of all major randomised clinical trials[J].Lancet,2002,359(9302) : 189- 198.
  • 3Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST Elevation Myocardial Infarction: [J]. Circulation, 2008,117(2): 296- 329.
  • 4Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirnfiban with aspirin plus heparin for unstable angina [J]. NEnglJ Med,1998,338(21):1498-1505.
  • 5The PRISM PLUS Study Investigators: Inhibition of the platelet glycoprotein II b/III a receptor with tirofiban in unstable angi na and non-Q wave myocardial infarction [J].N Engl J Med, 1998,338(21) :1488- 1497.
  • 6The RESTORE Investigators: Effects of platelet glycoprotein II b/III a blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J].Circulation, 7997,96(5) : 1445-1453.
  • 7Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial[J]. JAMA, 2008,299(15) :1788 -1799.
  • 8Gian B, Cinzia C, Marco S,et al. , Variability in Extent of Platelet Function Inhibition After Administration of Optimal Dose of Glycoprotein II b/III a Receptor Blockers in Patients Undergoing a High Risk Percutaneous Coronary Intervention [J]. Am J CardioI, 2006, 97(4) : 489- 493.
  • 9Wayne B, Thaddeus R, Yao H, et al,Randomized COMparison of platelet inhibition with abciximab, WiRofiban and epti fibatide during percutaneous coronary intervention in acute coronary syndromes: The COMPARE Trial. [J].Circulation, 2002,106(12) : 1470-1476.
  • 10Topol EJ, Moliterno DJ,et al. Herrmann HC,Comparison of two platelet glycoprotein II b/III a inhibitors, tirofiban and abciximab, for prevention of ischemic events with percutane ous coronary revascularization [J]. N Engl J Med , 2001, 344(25) : 1888-1894.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部